Cargando…
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antivir...
Autores principales: | Holubovska, Olha, Bojkova, Denisa, Elli, Stefano, Bechtel, Marco, Boltz, David, Muzzio, Miguel, Peng, Xinjian, Sala, Frederico, Cosentino, Cesare, Mironenko, Alla, Milde, Jens, Lebed, Yuriy, Stammer, Holger, Goy, Andrew, Guerrini, Marco, Mueller, Lutz, Cinatl, Jindrich, Margitich, Victor, te Velthuis, Aartjan J. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814846/ https://www.ncbi.nlm.nih.gov/pubmed/33469600 http://dx.doi.org/10.1101/2021.01.05.21249237 |
Ejemplares similares
-
Enisamium Inhibits SARS-CoV-2 RNA Synthesis
por: Elli, Stefano, et al.
Publicado: (2021) -
Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity
por: te Velthuis, Aartjan J. W., et al.
Publicado: (2021) -
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells
por: Boltz, David, et al.
Publicado: (2018) -
Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
por: Walker, Alexander P, et al.
Publicado: (2020) -
In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide
por: Haltner-Ukomadu, Eleonore, et al.
Publicado: (2018)